Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.153
Sell
RSI(14)
37.470
Neutral
STOCH(KDJ)(9,3,3)
29.285
Neutral
ATR(14)
0.373
High Vlolatility
CCI(14)
-131.233
Sell
Williams %R
68.456
Sell
TRIX(12,20)
-0.322
Sell
StochRSI(14)
49.820
Buy
Search
Neuraxis Inc
NRXSAdd to Watchlist
6.250USD
-0.010-0.16%
Close 07-31 16:00（ET）Quotes delayed by 15 min
71.56MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-0.16%
5 Days
-8.09%
1 Month
-11.72%
6 Months
+47.75%
Year to Date
+37.67%
1 Year
+150.00%
Key Figures
6.270Open
6.370High
42.90KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.37%Turnover Ratio
6.280Prev. Close
6.140Low
118.23KTurnover
LossP/E Static
12.46P/B
0.00%Div Yield TTM
-123.70%ROA
9.33052wk High
0.37Volume Ratio
-8.45MNet Profit
11.45MShares
-0.7927EPS TTM
--Beta
-269.22%ROE
2.19652wk Low
3.66%Amplitude
86.42%Gross Margin
71.56MMarket Cap
-2.80Reward/Risk
4.39%Risk Rate
TradingKey Stock Score of Neuraxis Inc
Currency: USD Updated: 2026-07-31Key Insights
Neuraxis Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 98 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neuraxis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Neuraxis Inc Highlights
StrengthsRisks
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 45.09% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.57M.
Undervalued
The company’s latest PE is -7.88, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.57M shares, decreasing 17.72% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.000
Target Price
0.00%
Upside Space
Neuraxis Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
109
Total
7
Median
9
Average
Company name
Ratings
Analysts
Neuraxis Inc
NRXS
2
Stryker Corp
SYK
32
Dexcom Inc
DXCM
32
Zimmer Biomet Holdings Inc
ZBH
31
Medtronic PLC
MDT
31
Abbott Laboratories
ABT
29
1
2
3
...
22
Indicators
Moving Average
Indicators
Value
Direction
MA5
6.368
Sell
MA10
6.639
Sell
MA20
6.832
Sell
MA50
6.967
Sell
MA100
7.202
Sell
MA200
5.527
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Neuraxis Inc Info
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Ticker SymbolNRXS
CompanyNeuraxis Inc
CEOCarrico (Brian Allen)
Websitehttps://neuraxis.com/
Shareholders
Related Instruments
-1.72%
-0.43%
+0.12%
-0.59%
-0.74%
+0.10%
-6.42%
-0.36%
+1.75%
-0.14%
-2.99%
+1.58%
-0.29%
-1.02%
+0.13%
+0.05%
-0.80%
-0.24%
-0.70%
-0.78%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Neuraxis Inc (NRXS)?
The current price of Neuraxis Inc (NRXS) is 6.25.
What is the symbol of Neuraxis Inc?
The ticker symbol of Neuraxis Inc is NRXS.
What is the 52-week high of Neuraxis Inc?
The 52-week high of Neuraxis Inc is 9.33.
What is the 52-week low of Neuraxis Inc?
The 52-week low of Neuraxis Inc is 2.20.
What is the market capitalization of Neuraxis Inc?
The market capitalization of Neuraxis Inc is 71.56M.
Is Neuraxis Inc (NRXS) currently rated as Buy, Hold, or Sell?
According to analysts, Neuraxis Inc (NRXS) has an overall rating of Buy, with a price target of 11.00.
What is the Earnings Per Share (EPS TTM) of Neuraxis Inc (NRXS)?
The Earnings Per Share (EPS TTM) of Neuraxis Inc (NRXS) is -0.95.